In the 2022 WHO classification, this disease subtype has been broken up further into molecularly defined entities including TFE3-rearranged RCC (Xp11 translocation RCC) and TFEB-altered RCC, given the different behaviors of these specific subtypes [2]. This evidence concerns the gene TFEB and renal cell adenocarcinoma.